Literature DB >> 3180516

Fractures and vertebral bone mineral density in patients with renal osteodystrophy.

B Piraino1, T Chen, L Cooperstein, G Segre, J Puschett.   

Abstract

We investigated the relationship of CT determined vertebral bone mineral density (BMD), type of renal osteodystrophy, N terminal PTH levels and fracture history in 31 dialysis patients. BMD for patients with bone biopsy documented osteitis fibrosa was 1.6 standard deviation (SD) above the normal value for age and sex matched controls, while those patients with low turnover osteodystrophy had a mean BMD 1.2 SD below normal (p less than 0.0001). Three patients with osteitis fibrosa who had previously been treated with prednisone had a low BMD (1.8 SD below normal, different than O, p = 0.0015). There was no correlation between BMD and time on dialysis (r = 0.1). An N terminal PTH level greater than 150 pg/ml was a sensitive (94%) and specific (100%) method of separating those patients with osteitis fibrosa from those with low turnover osteodystrophy, while BMD was much less useful in this differentiation. A low BMD was not predictive of fracture history but the type of renal osteodystrophy was. Patients with low turnover osteodystrophy had a fracture rate of 0.2 fractures/dialysis year in comparison to those with osteitis fibrosis who had 0.1 fractures/dialysis year. Patients with the former bone disease fractured mainly axial rather than appendicular bones in contrast to those patients with osteitis fibrosa. In conclusion we found that patients with osteitis fibrosa had increased BMD compared to normal while those with low turnover osteodystrophy had decreased BMD, but that the N terminal PTH level was a better predictor of the type of bone disease present than was BMD.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180516

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  30 in total

1.  Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis.

Authors:  A-J Chang; Q Ying; X-N Chen; W-M Wang; N Chen
Journal:  Osteoporos Int       Date:  2016-07-08       Impact factor: 4.507

Review 2.  Assessment of bone mass following renal transplantation in children.

Authors:  Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

3.  Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients.

Authors:  Jong Chan Park; Csaba P Kovesdy; Uyen Duong; Elani Streja; Mehdi Rambod; Allen R Nissenson; Stuart M Sprague; Kamyar Kalantar-Zadeh
Journal:  Hemodial Int       Date:  2010-03-24       Impact factor: 1.812

4.  Association between high-molecular-weight adiponectin and bone mineral density in hemodialysis patients.

Authors:  Nobuyuki Amemiya; Shigeru Otsubo; Yuko Iwasa; Takako Onuki; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-11-14       Impact factor: 2.801

5.  The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease.

Authors:  S A Jamal; S L West; T L Nickolas
Journal:  Osteoporos Int       Date:  2013-10-11       Impact factor: 4.507

Review 6.  Bone imaging and fracture risk assessment in kidney disease.

Authors:  Sophie A Jamal; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

Review 7.  Can one evaluate bone disease in chronic kidney disease without a biopsy?

Authors:  Revekka Babayev; Thomas L Nickolas
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

8.  Trabecular bone structure in patients with primary hyperparathyroidism.

Authors:  M Vogel; M Hahn; G Delling
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Differences in bone quality in low- and high-turnover renal osteodystrophy.

Authors:  Hartmut H Malluche; Daniel S Porter; Marie-Claude Monier-Faugere; Hanna Mawad; David Pienkowski
Journal:  J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 10.121

10.  Spontaneous regression of hypercalcemia in a patient with primary hyperparathyroidism and prolactinoma.

Authors:  V Baskar; D Kamalakannan; B M Singh; J Odum
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.